NutrMetab (Lond) (2005) 2:22
If the patient is treated with both oral hypoglycemic drugs and an injectable non-insulin antidiabetic drug, assign codes Z79.84, Long term (current) use of oral hypoglycemic drugs, and Z79.85, Long-term (current) use of injectable non-insulin antidiabetic drugs
Rarely, musculoskeletal pain has been reported as a side effect of semaglutide, though it is unclear whether this is related to the drug itself or to other factors, such as changes in weight or activity levels
These tests help assess the overall effectiveness of diabetes management, including the impact of sitagliptin
Overall, the safety and tolerability profile for oral semaglutide in PIONEER 12 was consistent with the results from the global PIONEER trials and with the general safety profile of the GLP-1RA drug class [27]